Before bidding adieu to the acronym DOTY for eleven months, it seems only fair to offer our winners a chance to share their enthusiasm for joining that select group of companies worthy of The Roger. We now turn the microphone over to David Schenkein, MD, CEO of Agios Pharmaceuticals, which along with partner Celgene captured the Alliance Deal of the Year for its big sib/little sib tie-up in cancer metabolism.
On behalf of Agios and with appreciation for our alliance partner Celgene, it is my most profound privilege and honor to accept the award for Alliance Deal of the Year from that venerable and peerless institution of biotechnology authority and sagacity, the IN VIVO Blog.
This was a hard fought battle. Our invaluable ally Celgene was staunch and steadfast. Our opponents were worthy, resilient and noble.
We fought on the beaches; we fought on the landing grounds; we fought on Facebook and in the Apple stores; we fought with the support of our many CRO's across the world. We never surrendered.
Never in the field of business conflict was so much owed by so many to so few (voters).
Let us therefore brace ourselves to our duties, and so bear ourselves that, if Agios lasts for a thousand years, people will still say, "This was their finest hour."
We look forward to receiving our Roger. We know just where to put it.